logo

Indian News

Share SHARE

anipharma-081817.jpg In today's Spotlight column, the company we are featuring is ANI Pharmaceuticals Inc. (ANIP).

VishalSikka-Infosys-081817.jpg Shares of Infosys Technologies Ltd. were losing around 10 percent in Indian trading on Friday after the Software exporter announced that Vishal Sikka has resigned as the Managing Director and Chief Executive Officer with immediate effect. The company appointed current chief operating officer Pravin Rao as the Interim-Managing Director and Chief Executive Officer.

Pharma-081817.jpg Today's Daily Dose brings you news about expanded FDA approval of AstraZeneca's ovarian cancer drug Lynparza; positive results from Endologix's LEOPARD trial; Fluidigm's licensing agreement with Baylor Genetics; Humana and Amgen's partnership to improve health outcomes and efficiency and Pfizer's Besponsa getting thumbs up from the U.S. regulatory agency.

Aug17-081717.jpg The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of August 17, 2017.

Slide0-Alzheimers-081717.jpg The development of Alzheimer's drugs has been marred by a high failure rate. A U.S. study, which analyzed how the Alzheimer's clinical trials fared during the period of 2002 to 2012, revealed a failure rate of 99.6% compared to a failure rate of 81% for cancer drugs.

Pharma-081717.jpg Today's Daily Dose brings you news about Acadia Healthcare's secondary offering; ARCA's progress in GENETIC-AF trial; Iovance's milestone that has boosted investor optimism; Psychemedics' role to play testing of drugs of abuse; Seattle Genetics' upcoming regulatory catalyst and inspection classification of Valeant's Bausch + Lomb manufacturing facility in Tampa, Florida.

Aug16-081617.jpg The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of August 16, 2017.

Pharma-081617.jpg Today's daily dose brings you news about patent protection of Alexion's Soliris; approval of Amicus' Fabry disease drug in Australia; mixed results from Bristol-Myers' CheckMate -214 trial; FibroGen's stock offering; ObsEva's upcoming milestones; Portola's regulatory catalyst and patent litigation related to Supernus' antieleptic drug Oxtellar XR.

Follow RTT